Df-IA2BM-Zr-89 - ImaginAb

Drug Profile

Df-IA2BM-Zr-89 - ImaginAb

Alternative Names: [89Zr]Df-IAB2M; IAB2M; IAB2M PSMA minibody; IAB2M PSMA PET imaging agent

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImaginAb Inc
  • Class Antibody diagnostics; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I/II Glioma

Most Recent Events

  • 13 Feb 2017 ImaginAb completes a phase I/II trial in Glioma (Diagnosis) in Japan (IV) (UMIN000018639)
  • 01 Jul 2016 ImaginAb completes a phase II trial for Prostate cancer (Diagnosis) in USA (NCT02349022)
  • 01 Jun 2016 ImaginAb completes a phase I/II trial in Prostate caner (Diagnosis, Metastatic disease) in USA (NCT01923727)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top